| Sep 2 |
Bristol Myers Squibb’s CAMZYOS offers benefits in oHCM trial
|
| Sep 1 |
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
|
| Sep 1 |
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
|
| Aug 31 |
How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock
|
| Aug 30 |
Bristol Myers Squibb (BMY) Advances But Underperforms Market: Key Facts
|
| Aug 30 |
Exact Sciences (EXAS) Up 7.5% Since Last Earnings Report: Can It Continue?
|
| Aug 29 |
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
|
| Aug 29 |
Repligen (RGEN) Down 13.1% Since Last Earnings Report: Can It Rebound?
|
| Aug 29 |
Bristol-Myers Squibb (NYSE:BMY) investors are sitting on a loss of 17% if they invested three years ago
|
| Aug 28 |
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
|
